Purpose: This study aimed to explore the effect of molecular targeted therapy combined with radiotherapy on the expression and prognostic value of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in bone metastasis of lung cancer.
Methods: 82 patients with bone metastases of lung cancer who underwent targeted therapy combined with radiotherapy in Hubei Cancer Hospital were regarded as the experimental group, and another 64 patients with bone metastases of lung cancer who underwent conventional radiotherapy were regarded as the control group. Serum VEGF and COX-2 levels were measured by enzyme-linked immunosorbent assay (ELISA) before and after the treatment. The efficacy and adverse reactions of both groups were compared.
Results: The levels of COX-2 and VEGF in serum of both groups were significantly lower than those before treatment (p<0.05). The effective rate and local tumor efficiency of the experimental group were significantly higher than those of the control group (p<0.05). The diarrhea and asthenia and vomiting events in the experimental group were significantly lower than those in the control group (p<0.05). No significant differences were found between the two groups in other adverse reactions (p>0.05). A significant positive correlation was found between COX-2 and VEGF in serum in the two groups before and after treatment; the survival rate of COX-2 and VEGF high expression group was significantly lower than in the low expression group (p<0.05); ECOG score, pathological type, COX-2 and VEGF level were independent risk factors of death in the experimental group.
Conclusion: Targeted therapy combined with radiotherapy has a strong inhibitory effect on the expression of COX-2 and VEGF in bone metastasis of lung cancer. There was a significant positive correlation between the expression of COX-2 and VEGF, and the use of targeted therapy combined with radiotherapy can significantly improve the efficacy and quality of life and to prolong survival.